Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, Stenglein S, Seyfried S, Wahn U; DUAL study group. Kopp MV, et al. Among authors: sieder c. Clin Exp Allergy. 2009 Feb;39(2):271-9. doi: 10.1111/j.1365-2222.2008.03121.x. Epub 2008 Oct 30. Clin Exp Allergy. 2009. PMID: 19016798 Clinical Trial.
Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, Reich K, Ruëff F, Schäkel K, Sengupta K, Sieder C, Simon JC, Wedi B, Zuberbier T, Mahler V, Staubach P. Maurer M, et al. Among authors: sieder c. J Allergy Clin Immunol. 2011 Jul;128(1):202-209.e5. doi: 10.1016/j.jaci.2011.04.038. Epub 2011 Jun 2. J Allergy Clin Immunol. 2011. PMID: 21636116 Clinical Trial.
A double-blind, randomized, placebo/active controlled crossover evaluation of the efficacy and safety of Ritalin ® LA in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting.
Schulz E, Fleischhaker C, Hennighausen K, Heiser P, Oehler KU, Linder M, Haessler F, Huss M, Warnke A, Schmidt M, Schulte-Markworth M, Sieder C, Klatt J, Tracik F. Schulz E, et al. Among authors: sieder c. J Child Adolesc Psychopharmacol. 2010 Oct;20(5):377-85. doi: 10.1089/cap.2009.0106. J Child Adolesc Psychopharmacol. 2010. PMID: 20973708 Clinical Trial.
Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial.
Sticherling M, Mrowietz U, Augustin M, Thaçi D, Melzer N, Hentschke C, Kneidl J, Sieder C, Reich K. Sticherling M, et al. Among authors: sieder c. Br J Dermatol. 2017 Oct;177(4):1024-1032. doi: 10.1111/bjd.15707. Epub 2017 Sep 12. Br J Dermatol. 2017. PMID: 28580646 Clinical Trial.
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
Dresemann G, Weller M, Rosenthal MA, Wedding U, Wagner W, Engel E, Heinrich B, Mayer-Steinacker R, Karup-Hansen A, Fluge O, Nowak A, Mehdorn M, Schleyer E, Krex D, Olver IN, Steinbach JP, Hosius C, Sieder C, Sorenson G, Parker R, Nikolova Z. Dresemann G, et al. Among authors: sieder c. J Neurooncol. 2010 Feb;96(3):393-402. doi: 10.1007/s11060-009-9976-3. Epub 2009 Aug 18. J Neurooncol. 2010. PMID: 19688297 Clinical Trial.
Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, Korn S. Buhl R, et al. Among authors: sieder c. Thorax. 2015 Apr;70(4):311-9. doi: 10.1136/thoraxjnl-2014-206345. Epub 2015 Feb 12. Thorax. 2015. PMID: 25677679 Free PMC article. Clinical Trial.
51 results